Search results - 3 results
Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework.
ImmunoAssay (GP5 +/6+ EIA) using the VALGENT (VAL idation of HPV GEN otyping Tests) framework. METHODS: Clinical performance was assessed using 998 unselected, cervical screening samples enriched with 297 ...
Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.
+/6+ PCR, with a genotyping readout as an alternative for the more established enzyme immunoassay (EIA) detection of 14 targeted high-risk human papillomavirus (HPV) types. LMNX is additionally provided ...
Chapter 10: HPV testing on cervical cancer specimens: which assay can be used in cervical cancer screening.
tests (validated in population-based randomised trials: Hybrid Capture 2 HPV DNA Test; GP5 +/6+ PCR- EIA. hrHPV DNA tests validated consistently in multiple studies against standard comparator tests: ...